Atopic Dermatitis Drugs Market to Reach US$ 28.2 Billion by 2031| States TMR

The latest research study released by Transparency Market Research on "𝐀𝐭𝐨𝐩𝐢𝐜 𝐃𝐞𝐫𝐦𝐚𝐭𝐢𝐭𝐢𝐬 𝐃𝐫𝐮𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐭𝐨 𝟐𝟎𝟐𝟑-𝟐𝟎𝟑𝟏 ″ research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Atopic Dermatitis Drugs industry, as well as predicted future growth, technological advancements, investment prospects, market economics, and financial data.

Atopic Dermatitis Drugs market is estimated to attain a valuation of US$ 28.2 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 8.9% during the forecast period, 2023-2031

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐎𝐟 𝐓𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 -https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=73639

Rise in prevalence of atopic dermatitis is driving the global atopic dermatitis drugs market. Prevalence of atopic dermatitis has been increasing, with a significant rise in both adults and children. Introduction of innovative therapies and treatment options for atopic dermatitis are expected to propel market expansion. Furthermore, increase in demand for biologics, rise in new product approvals, and surge in healthcare expenditure, especially in developing countries, are likely to bolster the global atopic dermatitis drugs market size during the forecast period.

Development of effective and targeted therapies for atopic dermatitis offers lucrative opportunities to market players. Leading companies are focusing on improving access to healthcare services and providing affordable treatments such as targeted biologic therapies and topical medications in order to increase market share.

𝐋𝐚𝐭𝐞𝐬𝐭 𝐕𝐞𝐫𝐬𝐢𝐨𝐧 𝐨𝐟 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐈𝐧𝐜𝐥𝐮𝐝𝐞𝐬:

Detailed industry forecast
Brief Introduction to the research report.
Additional information on company participants
Customized reports and analyst assistance are available upon request.
Recent market developments and potential future growth opportunities
Personalized regional/country reports upon request
New data sources are being integrated.
Increased focus on data privacy and security
Increased collaboration and co-creation

𝐄𝐧𝐪𝐮𝐢𝐫𝐞 𝐁𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠 - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=73639

𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐎𝐮𝐭𝐥𝐨𝐨𝐤

Atopic dermatitis is relatively common in North America, with a significant number of individuals affected by the condition. This high prevalence drives demand for effective treatments and contributes to the expansion of the market.

As per atopic dermatitis drugs market research, the U.S. is likely to dominate the industry during the forecast period owing to its large patient population and usage of biologic drugs in the affected population of patients with atopic dermatitis.

According to the National Eczema Association, around 9.6 million U.S. children under the age of 18 have atopic dermatitis, and one-third have moderate-to-severe disease. An estimated 16.5 million U.S. adults (7.3%) have atopic dermatitis, with nearly 40% affected by moderate-to-severe disease.

North America boasts a well-developed healthcare infrastructure, including hospitals, specialized dermatology clinics, research institutions, and pharmaceutical companies. This infrastructure supports the diagnosis, treatment, and development of new therapies for atopic dermatitis.

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐨𝐫 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:

Sanofi, Pfizer, AbbVie, Leo Pharma, Eli Lilly, Teva Pharmaceutical Industries Ltd, and Novartis AG

𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 -

𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐓𝐲𝐩𝐞

Biologics
Others

𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥

Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies

𝐇𝐚𝐯𝐞 𝐀𝐧𝐲 𝐐𝐮𝐞𝐫𝐲? 𝐀𝐬𝐤 𝐓𝐨 𝐀𝐧𝐚𝐥𝐲𝐬𝐭: https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=73639

𝐊𝐞𝐲 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐆𝐥𝐨𝐛𝐚𝐥 𝐀𝐭𝐨𝐩𝐢𝐜 𝐃𝐞𝐫𝐦𝐚𝐭𝐢𝐭𝐢𝐬 𝐃𝐫𝐮𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭

In October 2022, LEO Pharma announced that the European Commission (EC) extended the marketing authorization for Adtralza (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.

In August 2021, the European Commission (EC) approved RINVOQ (upadacitinib) as the first JAK inhibitor in the European Union for the treatment of both adults and adolescents with moderate to severe atopic dermatitis. The approval was based on the results of two phase 3 clinical trials, which showed that RINVOQ was effective at reducing the signs and symptoms of atopic dermatitis, including itching, redness, swelling, and oozing.

𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐥𝐞𝐭𝐬 𝐲𝐨𝐮 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐲 𝐭𝐡𝐞 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐢𝐧 𝐀𝐭𝐨𝐩𝐢𝐜 𝐃𝐞𝐫𝐦𝐚𝐭𝐢𝐭𝐢𝐬 𝐃𝐫𝐮𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐛𝐲 𝐦𝐞𝐚𝐧𝐬 𝐨𝐟 𝐚 𝐫𝐞𝐠𝐢𝐨𝐧:

North America (the United States, Canada, and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))
South America (Brazil etc.) The Middle East and Africa (North Africa and GCC Countries)

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 -

𝐒𝐮𝐥𝐟𝐮𝐫 𝐌𝐚𝐫𝐤𝐞𝐭- https://www.globenewswire.com/news-release/2022/07/19/2482024/0/en/Sulfur-Market-for-Mining-Application-is-Estimated-to-Progress-at-a-CAGR-of-6-6-during-the-Forecast-Period-TMR-Report.html

𝐀𝐮𝐭𝐨𝐦𝐨𝐭𝐢𝐯𝐞 𝐀𝐢𝐫𝐛𝐚𝐠 𝐌𝐚𝐫𝐤𝐞𝐭- https://www.globenewswire.com/news-release/2022/07/19/2482137/0/en/Automotive-Airbag-Market-to-Reach-US-22-7-Bn-by-2031-New-Features-to-Enhance-Passenger-Safety.html

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬

Nikhil Sawlani

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

This release was published on openPR.